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Abstract The red cell membrane is comprised of a lipid bilayer 
studded with transmembrane proteins, and laminated by a protein 
network, the membrane skeleton, at the surface of the inner 
monolayer. The erythrocyte owes its mechanical properties to the 
membrane skeleton. Hereditary spherocytosis, hereditary ellipto- 
cytosis or poikilocytosis, Southeast Asian ovalocytosis are hered- 
itary hemolytic anemias, due to mutations in the genes encoding 
ankyrin, the anion exchanger, spectrin, protein 4.1 or protein 4.2, 
which are main proteins of the membrane. Recent advances in the 
field have led to fundamental questions. 
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1. Introduction 
The red cell membrane iscomprised of a lipid bilayer studded 
by numerous transmembrane proteins, many of which are in- 
volved in exchange processes. The phospholipids have an 
assymetric distribution. Glycan moieties, covalently linked to 
transmembrane proteins and sphingolipids, and glyco- 
sylphosphatidylinositol-anchored proteins (GPI-proteins), pro- 
trude on the outer side. The inner monolayer of the surface is 
laminated by a protein assembly, the red cell (or membrane) 
skeleton. Over several years, many mutations have been found 
in abnormal red cell membrane proteins. Blood group antigens 
and/or GPI-proteins will be not to delt with here. 
2. The red cell membrane and its skeleton 
The red cell must achieve remarkable mechanical perform- 
ances, that is, endure the turbulences prevailing in large vessels 
and negociate their passing through capillaries. These proper- 
ties are ensured by the red cell skeleton in connection with some 
transmembrane proteins. Fig. 1 provides a cross-section of the 
membrane and its skeleton. Table 1 gives the most salient data 
pertaining to the main proteins and their genes. A number of 
significant features may be pinpointed [1]. 
1. All the proteins envisaged are widely distributed among 
cell-types through a spectrum of isoforms. Isoforms diversity 
derives mainly from gene multiplication (spectrin chains, 
ankyrin, anion exchanger) and/or alternative splicing of the 
transcript from a single gene (protein 4.1, protein 4.2). 
2. Ankyrin contains three functional domains : 89 kDa (bind- 
ing site for band 3), 63 kDa (binding site for spectrin ft-chain) 
and 55.5kDa ('regulatory domain') [2]. The 89 kDa domain is 
comprised of 24 homologous segments of 33 amino acids. This 
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recurrent motif is found in a variety of proteins, such as NF- 
xD, a transcription factor precursor [3]. The multiprotein com- 
plex held together by ankyrin connects the skeleton to trans- 
membrane proteins. The primary absence of one protein is 
likely to disrupt the whole complex, at least in part, and yield 
a reduction or the absence of other proteins. 
3. Basically, the anion exchanger (AE1), also designated band 
3, has a cytoplasmic domain (amino acids lto 403) and a mem- 
brane domain comprising 14 membrane-spanning segments 
(TM1 to 14; amino acids 40~882) [4]. The cytoplasmic domain 
binds the N-terminal, 89 kDa domain of ankyrin. It also binds 
protein 4.2 and many other proteins. Band 3 exists as immobile 
tetramers, bound to ankyrin and spectrin, and mobile dimers. 
4. Protein 4.2 has homologies with transglutaminases [5]. It 
binds to the cytoplasmic domain of the anion exchanger. Its 
N-terminal glycyl residue is acylated by myristic acid. 
5. Each a- and ft-spectrin chains are comprised of 106 amino 
acids homologous segments (al to a22, and ftl to ftl7, respec- 
tively) [6,7]. In space, the conformation units are described by 
two models [8,9], that both imply three a-helical segments. The 
phasing of conformational units is shifted downstream by 
26amino acids with respect o that of homologous egments 
[10]. An a- and aft-chain of spectrin initiate dimerization at two 
complementary nucleation sites, one on the a-chain (a18 to 
a21), the other on the ft-chain (ill to ft4) [11]. Then, the two 
chains complete dimerization by laying alongside in an antipar- 
allel fashion. Two dimers self-associate h ad to head through 
complementary sites located near the N- and C-termini of the 
a- and ft-chains, respectively. 
6. The transcript of protein 4.1 is the subject of complex splic- 
ing patterns that are cell and stage-specific [12,13]. For exam- 
ple, in the early erythroid precursors, the 5'-portion (17 nt) of 
exon 2, containing the main initiation codon, is conserved 
whereas exon 16 (63 nt) is skipped. The situation reverses at a 
latter stage, though non-synchronically. Then, a downstream 
ATG (exon 4) ensures entirely the initiation of translation. 
Exon 16, along with exon 17, complete the binding site of 
protein 4.1 for the spectrin-actin complex. 
7. p55 and glycophorin C anchor protein 4.1 to the bilayer, p55 
is palmitoylated, has a SH3 domain and a guanylate kinase 
activity[14]. Its homologue in Drosophila acts as a tumor sup- 
pressor. Glycophorin C interacts with protein 4.1 and GPC 
through its cytoplasmic segment [15]. 
3. Hereditary spherocytosis 
Hereditary spherocytosis (HS) is the most common (approx. 
112000 kindreds) of congenital hemolytic anemia [1]. Icterus, 
anemia, splenomegaly and biliary stones are the main signs. 
The whole spectrum of gravity may be covered, from no clinical 
expression at all to death in utero (hydrops fetalis). HS occurs 
in nearly all ethnic groups, but appears more seldom among 
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black people. The inheritance pattern is dominant or reces- 
sive. Yet, compounded modes of transmission are often re- 
corded. 
3.1. Ankyrin 
70% of HS cases stems from ankyrin mutations. Twenty 
percent of these mutations would be de novo. Most of HSmu- 
tations are 'private', being restricted to one or a few families. 
A number of mutations lead to the absence of one haploid set 
of ankyrin [16] or the truncation of the latter molecule [17]. 
These forms display a dominant inheritance pattern. The de- 
crease of ankyrin yields a secondary reduction in protein 4.2 
and, inconstantly, in spectrin. Other ankyrin mutations are 
simple amino-acid substitutions [1]. Two such mutations in 
trans to one another are required to produce a clinical picture, 
that is often severe. The nb/nb mouse (nb: normoblastosis) dis- 
closes HS and a delayed neurological syndrome associated with 
degenerating Purkinje cells [18], both stemming from an ANK1 
gene mutation. 
3.2. Anion exchanger 
25% of HS cases are associated with a 20-40% reduction of 
the anion exchanger (AEI). The responsible mutations are ei- 
ther stop codons that suppress the synthesis of one AEI haploid 
set, or mutations that prevent AE1 from being conveyed and/or 
inserted into the membrane [19-21]. The clinical picture is of 
intermediate severity but often requires splenectomy at last. 
Basically, the inheritance pattern is dominant. Some AE1 muta- 
tions hit specifically the binding site for protein 4.2 [22]. While 
these mutations remain symptomless in the heterozygous state, 
they produce a severe picture in the homozygous tate. The 
main biochemical feature, then, is the lack of protein 4.2 
whereas the amount of AE1 is normal (or nearly so). A deletion 
of 9 nt [23,24], involving the very junction of the AE 1 cytoplas- 
mic and membrane domains, is the cause of Southeast Asian 
ovalocytosis in the heterozygous state (the homozygous tate 
must be lethal). 
3.3. Protein 4.2 
Protein 4.2 total deficiency, arising now from mutations in 
protein 4.2 gene itself, yields a somewhat atypical form of HS 
(scarce spherocytes, nearly normal osmotic resistance) in the 
homozygous tate [25 27]. It has a recessive inheritance pat- 
tern. Except for two cases, the mutations are single amino acid 
substitutions and it is not always understood why they result 
in the lack of protein 4.2. One allele, allele NIPPON, appears 
in a recurrent fashion in Japan [25]. 
3.4. Spectrin 
A few mutations of spectrin ft-chain have been found to be 
responsible for HS in the heterozygous state in man [28 30] and 
one nonsense mutation does so in the ja/ja mouse[31]. The 
mutation may occur all over theft-chain molecule, except in the 
ftl7 homologous segment. The mouse displays an array of spec- 
trin ~-gene mutations liable to cause HS. 
4. Hereditary elliptocytosis 
Hereditary elliptocytosis (HE) is the second most common 
hereditary hemolytic anemia [1]. The clinical features are not 
very different from those of HS, yet they are usually milder. 
Diagnosis relies on the presence of elliptic red cells on smears. 
The severe forms achieve hereditary poikilocytosis (HP): on 
smears, elliptocytes are replaced by cells having all sorts of 
shapes and sizes (poikilocytosis). HE is quite evenly distributed 
in ethnic groups, but are more common among black people. 
The inheritance pattern is dominant or recessive, however 
many compounded patterns are also observed. 
4.1. Spectrin or- and fl-chains 
The HE mutations are clustered in the self-association sites 
of the c~-chain (c~l homologous egment) and of the ft-chain 
(ill 7 homologous segment) [32,33]. In addition, some mutations 
are more remote from the self-association site in the c~-chain, 
occurring down to homologous segment c~8. fl-Chain mutations 
often lead to truncation the C-terminal segment. At all events, 
the self-association process is disturbed. Most oftem mutations 
hit helix 3 of homologous egments, however changes altering 
helix 2 and even helix 1 (fl-chain) have been reported. 
Remarkably, any s-allele responsible for HE (c~ Hc alleles) 
Table 1 
Main features of the considered proteins and their genes. Some proteins are only mentioned in Fig. 1, not in the text. 
Amino acids Monomers Gene symbol and Gene size (kb) and Size of mRNA Disease 
(calculated MW) per cell chromosomal location exon number (kbl 
Spectrin c~-chain 2429 (281) 242 000 SPTA l; lq22-q23 80; 52 8 HE 
Spectrin fl-chain 2137 (246) 242 000 SPTB; 14q23 q24.2 > 100; 36 7.5 HE, HS 
Ankyrin 1880 (206) 124 000 ANK1; 8pl 1.2 > 120:42 6.8 7.2 HS 
Adducin c~-chain 737 (81) 30 000 ADDA; 4p16.1 
Adducin fl-chain 726 (80) 30 000 ADDB; 
Anion exchanger 9ll (102) 1 200000 EPB3; 17q12 q21 17; 20 4.7 HS 
Protein 4.1 588 (66) -200 000 ELI; lp33-p34.2 > 250; 23 5.6 HE 
Protein 4.2 691 (77) ~250000 ELP42; 15q15 q21 20; 13 2.4 HS ~' 
Dematin 383 (43) ~ 140 000 b 
(52) c ; 8p21.1 
p55 466 (53) ~80 000 MPP1; Xq28 ~30; 2 
fl-Actin 375 (42) 700 000 d ACTB; 7pter-q22 > 4:6 
Tropomodulin 359 (41) ~30 000 TMOD; 9q22 
Tropomyosin 239 (22) ~ 70 000 e TPM3; lq31 
Glycophorin C 128 (14) f GYPC; 2q14-q21 14; 4 1.4 HE 
Glycophorin D 107 (11) f } -200000 
These data are largely from reference 1; a: atypical form of HS; b: dematin occurs as trimers; c: determined MW; d: fl-actin occurs as oligomers (~ 14 
monomers); e:tropomyosin occurs as dimers; f: the contribution of the glycan moieties is not included in the MW; glycophorin D is an isoform of 
glycophorin C, the translation being initiated at Met22 of glycophorin C. 
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Fig. 1. Section of the erythrocyte membrane and skeleton. Only relevant proteins and some other major proteins are shown. AE1 : anion exchanger. 
GPC and GPD : glycophorins C and D, respectively. GPI-protein : glycosylphosphatidylinositol-anchored protein. Horizontal interactions: c~fl-dimers 
self-associate head-to-head to form ~82 heterotetramers; each of the extremities of the tetramers interacts with actin and protein 4.1 to form the 
junctional complex. This complex extends to a larger complex including adducin (~- and fl-chains), dematin, tropomyosin, tropomodulin (Table 1) 
and still other proteins. Vertical interactions: ,8-spectrin interacts with ankyrin that, in turn, interacts with the cytoplasmic domain of AE1. Protein 
4.1, p55 and GPC (GPD) combine into a distinct complex. 
yields two possible levels of clinical expression, schematically 
mild or severe. It has been shown that the aggravating factor 
is carried by the c~-allele in trans. Unless it is merely another ct HE 
mutation, it is more often a low expression allele, allele ct LELv 
(LELY: Low Expression LYon) [34,35]. Allele ~LELV carries 
two mutations: ~1857 Leu--,Val, a functionnally neutral poly- 
morphism, and a C to T substitution at position -12 of intron 
45. Remarkably, exon46 (18 nt), a normally constitutive exon, 
is skipped in 50% of a LELY  transcripts. Alpha-chains temming 
from c~ LELv allele compete defavourably with ~HEchains, that all 
contain, in principle, the 6 amino acids encoded by exon 46 and 
thereby are preferentially recruited by the fl-chains. Hence a 
prevalence of ~HEfldi . . . .  that will turn out to poorly self-associ- 
ate subsequently. Alpha LELv alleles appear with a uniform fre- 
quency (20-30%) in all ethnic groups investigated so far (Cau- 
casians, African Blacks, Japanese and Chinese) [36]. 
4.2. Protein 4.1 
4. l ( - )  HE may be associated with a reduction (heterozygous 
state) or the absence (homozygous state) of protein 4.1.4.1(-)  
alleles account for approximately 30% of HE cases among 
Caucasians. Heterozygous 4.1(-) HE is clinically silent. It is 
only manifested by a 20-30% decrease of protein 4.1. Excep- 
tional homozygous 4.1(-) HE yields a severe clinical presenta- 
tion and the total absence of protein 4.1. Due to the complexity 
of protein 4.1 gene and of the splicing of its transcript, only two 
mutations have been elucidated at the gene level so far [37,38]. 
In the homozygous tate, the absence of protein 4.1 yields a 
sharp decrease of glycophorin C [39] and abolishes the presence 
of protein p55 [40]. 
5. Conclusions 
Elucidating the mutations responsible for genetic disorders 
of the red cell membrane have delineated by default many 
important features of normal gene expression and protein func- 
tion. It opened new ways in fundamental research, and received 
important applications in diagnosis and treatment. 
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